Ludwig researchers devise and test pioneering personalized ovarian cancer vaccine
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | International Medicine & Public Health | Ovarian Cancer | Ovaries | Study | Vaccines